🧬 BDNF Extraction Viewer

Извлечено: 997 / 997 (100.0%) Средняя confidence: 0.13
← Назад к списку

Training Load Oscillation and Epigenetic Plasticity: Molecular Pathways Connecting Energy Metabolism and Athletic Personality.

PMID: 41596440 · DOI: 10.3390/ijms27020792 · International journal of molecular sciences, 2026 · Dan Cristian Mănescu
📄 Abstract

Training adaptation involves muscular-metabolic remodeling and personality-linked traits such as motivation, self-regulation, and resilience. This narrative review examines how training load oscillation (TLO)-the deliberate variation in exercise intensity, volume, and substrate availability-may function as a systemic epigenetic stimulus capable of shaping both physiological and psychological adaptation. Fluctuating energetic states reconfigure key energy-sensing pathways (AMPK, mTOR, CaMKII, and SIRT1), thereby potentially influencing DNA methylation, histone acetylation, and microRNA programs linked to PGC-1α and BDNF. This review synthesizes converging evidence suggesting links between these molecular responses and behavioral consistency, cognitive control, and stress tolerance. Building on this literature, a systems model of molecular-behavioral coupling is proposed, in which TLO is hypothesized to entrain phase-shifted AMPK/SIRT1 and mTOR windows, alongside CaMKII intensity pulses and a delayed BDNF crest. The model generates testable predictions-such as amplitude-dependent PGC-1α demethylation, BDNF promoter acetylation, and NR3C1 recalibration under recovery-weighted cycles-and highlights practical implications for timing nutritional, cognitive, and recovery inputs to molecular windows. Understanding TLO as an entrainment signal may help integrate physiology and psychology within a coherent, durable performance strategy. This framework is conceptual in scope and intended to generate testable hypotheses rather than assert definitive mechanisms, providing a structured basis for future empirical investigations integrating molecular, physiological, and behavioral outcomes.

Confidence: 0 · 0 полей извлечено
Идентификация (6 полей)
Механизм действия (21 полей)
Экспрессия (8 полей)
Tissue expression
—
0.00
In vitro
—
0.00
In vivo
—
0.00
In silico
—
0.00
Genetic association
—
0.00
Ex vivo
—
0.00
Animal model
—
0.00
Diet/model
—
0.00
Клиника (11 полей)
Drug
—
0.00
Indication
—
0.00
Patient subgroups
—
0.00
Safety concerns
—
0.00
Off-target
—
0.00
Trial stage
—
0.00
Pharma competitors
—
0.00
AE severity
—
0.00
MOA weight loss
—
0.00
Endpoints
—
0.00
Approved
—
0.00